Mylan in patent settlement with Shionogi, CIMA for Prednisolone ODTPharmaceutical Business ReviewMylan has signed a settlement and license agreements with Shionogi and CIMA Labs regarding Prednisolone sodium phosphate orally disintegrating tablets (ODT…
Syrian economy faces "heart failure" – Al-Bawaba
Syrian economy faces "heart failure"Al-Bawaba… Tunisia · UAE · Yemen · HOME · NEWS · BUSINESS · ENTERTAINMENT · SPORTS · WEATHER · EDITOR'S CHOICE · BLOGS ROUNDUP &mi…
Computer consultant died from liver failure cause by drinking – Get Bracknell
Computer consultant died from liver failure cause by drinkingGet BracknellA computer consultant who lost his job died from liver failure, an inquest heard last Thursday. Mukesh Vajeskanker Trivedy was found dead at his home in Uffington Drive, Bracknel…
Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
NEW YORK — Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced …
Mylan settles generic Orapred ODT patent litigation with Shionogi and CIMA Labs – pharmabiz.com
Mylan settles generic Orapred ODT patent litigation with Shionogi and CIMA Labspharmabiz.comMylan Inc. has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone sodium phos…
Usada's Lance Armstrong rap sheet – The Guardian
Usada's Lance Armstrong rap sheetThe Guardian1 Use and/or attempted use of prohibited substances and/or methods including EPO, blood transfusions, testosterone, corticosteroids and/or masking agents. 2 Possession of prohibited substances and/or met…
Research and Markets: Bone Marrow Transplantation – Pipeline Review, H2 2012 – The Herald | HeraldOnline.com
Research and Markets: Bone Marrow Transplantation – Pipeline Review, H2 2012The Herald | HeraldOnline.comDUBLIN — Research and Markets (http://www.researchandmarkets.com/research/glrzv3/bone_marrow) has announced the addition of Global Markets Direct…
BUSINESS WIRE: Biogen Idecs Engagement für multiple Sklerose auf 28 … – Vereinigte Wirtschaftsdienste
BUSINESS WIRE: Biogen Idecs Engagement für multiple Sklerose auf 28 …Vereinigte WirtschaftsdiensteDaclizumab High-Yield Process (DAC HYP) ist eine subkutan verabreichte Formulierung von Daclizumab im fortgeschrittenen Stadium der klinischen Entwickl…
Biogen Idecs Engagement für multiple Sklerose auf 28. ECTRIMS-Kongress … – Live-PR.com (Pressemitteilung)
Biogen Idecs Engagement für multiple Sklerose auf 28. ECTRIMS-Kongress …Live-PR.com (Pressemitteilung)The effect of daclizumab HYP on sustained disability progression in the SELECT trial (Der Einfluss von Daclizumab HYP auf das anhaltende Fortschrei…
BUSINESS WIRE: Biogen Idecs Engagement für multiple Sklerose auf 28 … – Finanztreff
BUSINESS WIRE: Biogen Idecs Engagement für multiple Sklerose auf 28 …FinanztreffDaclizumab High-Yield Process (DAC HYP) ist eine subkutan verabreichte Formulierung von Daclizumab im fortgeschrittenen Stadium der klinischen Entwicklung für die Thera…